PressFebruary 17, 2023 FSD Pharma Inc. Launches New Program Targeting Unmet Medical Needs for Alcohol Misuse
PressFebruary 17, 2023 SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
PressFebruary 17, 2023 Pioneering Delix Therapeutics Study Published in ‘Science’ Elucidates the Mechanism of Psychedelic-Induced Neuroplasticity
PressFebruary 17, 2023 Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
PressFebruary 17, 2023 Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
PressFebruary 17, 2023 Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
PressFebruary 17, 2023 First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
PressFebruary 17, 2023 Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
PressFebruary 17, 2023 Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability
BlogFebruary 16, 2023 Cody Shandraw, Founder of Healing REIT, Sits in the Investor Hotseat on February 23rd
PressFebruary 14, 2023 Filament Health Announces Second Psilocybin Supply Agreement with the Centre for Addiction and Mental Health
PressFebruary 14, 2023 Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv
PressFebruary 14, 2023 PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
PressFebruary 14, 2023 Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results
PressFebruary 10, 2023 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement
PressFebruary 10, 2023 Silo Pharma Inc. Partnering to Transform Health Care, Improve Patient Outcomes
PressFebruary 10, 2023 FSD Pharma Inc. Receipt of No Objection Letter from Health Canada Is Focus of Recent InvestmentPitch Media Video
PressFebruary 10, 2023 Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
PressFebruary 10, 2023 Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
BlogFebruary 9, 2023 Microdosing is Now Legal in Oregon—What Does it Mean for the Psilocybin Community?
